Efficacy and safety of generic voriconazole for treatment of invasive fungal infections

Not Applicable

• Conditions: Hematological aptientsImmunocomprimsed patientsTransplant recipients; invasive aspergillosis; fungal infection; voriconazole

• Registration Number: TCTR20180111001
• Lead Sponsor: Faculty of Medicine Siriraj Hospital, Mahidol University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-11
• Study Completion: 2020-09-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 95

Inclusion Criteria

Patients 18 years of age or older who diagnosed invasive fungal infection

Exclusion Criteria

History of voriconazole allergy
Received medication that have significant interactions with voriconazole

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Global response 12 weeks Satisfactory global response (decreased of lesion by 50% at week 12 with clinical improve

Secondary Outcome Measures

Name	Time	Method
Mortality week 4 and week 12 Dead rate,Safety first 12 weeks Adverse drug reactions